MedPath

European Lung Cancer Working Party

🇧🇪Belgium
Ownership
-
Employees
-
Market Cap
-
Website

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Recruiting
Conditions
Carcinoma, Non-Small-Cell Lung
Immunotherapy
First Posted Date
2020-07-10
Last Posted Date
2021-08-23
Lead Sponsor
European Lung Cancer Working Party
Target Recruit Count
300
Registration Number
NCT04465942
Locations
🇧🇪

Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet, Brussels, Belgium

🇧🇪

Department of Pneumology CHU Charleroi, Charleroi, Belgium

🇧🇪

Hôpital Mont-Godinne, Yvoir, Belgium

and more 2 locations

Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry

Conditions
Lung Neoplasm
First Posted Date
2017-12-11
Last Posted Date
2021-08-23
Lead Sponsor
European Lung Cancer Working Party
Target Recruit Count
200
Registration Number
NCT03368820
Locations
🇧🇪

Hôpital Saint-Joseph, Charleroi, Belgium

🇧🇪

CHU Tivoli, La Louvière, Belgium

🇧🇪

CH Peltzer-La Tourelle, Verviers, Belgium

and more 3 locations

Has Inflammation a Significant Implication in Lung Cancer Evolution?

Conditions
Lung Neoplasms
First Posted Date
2015-06-30
Last Posted Date
2021-08-23
Lead Sponsor
European Lung Cancer Working Party
Target Recruit Count
400
Registration Number
NCT02484872
Locations
🇧🇪

Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet, Brussels, Belgium

Bronchoscopy Assisted by Electromagnetic Navigation (EMN) in the Diagnosis of Small Pulmonary Nodules

Not Applicable
Completed
Conditions
Pulmonary Nodule Cm
Interventions
Procedure: Bronchoscopy
First Posted Date
2013-01-30
Last Posted Date
2022-04-04
Lead Sponsor
European Lung Cancer Working Party
Target Recruit Count
120
Registration Number
NCT01779388
Locations
🇧🇪

Institut Jules Bordet, Brussels, Belgium

Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer

Not Applicable
Completed
Conditions
Non Small Cell Lung Carcinoma
Interventions
Drug: Chemotherapy
First Posted Date
2009-03-18
Last Posted Date
2020-06-26
Lead Sponsor
European Lung Cancer Working Party
Target Recruit Count
70
Registration Number
NCT00864266
Locations
🇧🇪

Hôpital Ambroise Paré, Mons, Belgium

🇧🇪

Department of Pneumology Clinique Saint-Luc, Bouge, Belgium

🇧🇪

Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet, Brussels, Belgium

and more 3 locations

A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide

Phase 2
Completed
Conditions
Small Cell Lung Carcinoma
Interventions
Drug: Adriamycin, cyclophosphamide, vindesine, valproic acid
First Posted Date
2008-09-25
Last Posted Date
2015-02-12
Lead Sponsor
European Lung Cancer Working Party
Target Recruit Count
64
Registration Number
NCT00759824
Locations
🇧🇪

Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet, Brussels, Belgium

🇧🇪

Department of Pneumology CHU Charleroi, Charleroi, Belgium

🇧🇪

Department of Pneumology Hôpital Saint-Joseph, Gilly, Belgium

and more 2 locations

Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.

Conditions
Non Small Cell Lung Carcinoma
First Posted Date
2008-09-25
Last Posted Date
2021-08-23
Lead Sponsor
European Lung Cancer Working Party
Target Recruit Count
340
Registration Number
NCT00759382
Locations
🇧🇪

Department of Pneumology RHMS Hôpital de la Madeleine, Ath, Belgium

🇧🇪

Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet, Brussels, Belgium

🇧🇪

Department of Pneumology Hôpital Saint-Joseph, Gilly, Belgium

and more 3 locations

Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy

Phase 2
Terminated
Conditions
Non Small Cell Lung Carcinoma
Interventions
Procedure: Lobectomy followed by concomitant mediastinal chemoradiotherapy
First Posted Date
2008-04-18
Last Posted Date
2015-02-12
Lead Sponsor
European Lung Cancer Working Party
Target Recruit Count
75
Registration Number
NCT00661011
Locations
🇧🇪

Department of Pneumology Hospital Ixelles-Molière, Brussels, Belgium

🇧🇪

Department of Pneumology Centre Hospitalier de Mouscron, Mouscron, Belgium

🇧🇪

CH Peltzer-La Tourelle, Verviers, Belgium

and more 9 locations

Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer

Phase 3
Completed
Conditions
Small Cell Lung Carcinoma, Extensive Disease
Interventions
First Posted Date
2008-04-15
Last Posted Date
2015-02-12
Lead Sponsor
European Lung Cancer Working Party
Target Recruit Count
361
Registration Number
NCT00658580
Locations
🇪🇸

Medical Oncology Hospital de Sagunto, Valencia, Spain

🇬🇷

Hellenic Cancer Institute - St Savas Oncology Hospital, Athens, Greece

🇧🇪

Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet, Brussels, Belgium

and more 1 locations

Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer

Phase 3
Terminated
Conditions
Non-small Cell Lung Carcinoma
Interventions
Drug: Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel
Drug: Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel
First Posted Date
2008-03-12
Last Posted Date
2015-02-12
Lead Sponsor
European Lung Cancer Working Party
Target Recruit Count
125
Registration Number
NCT00633568
Locations
🇫🇷

Service de Pneumologie Centre Hospitalier de Douai, Douai, France

🇫🇷

Service de Pneumologie Hôpital de Hayange, Hayange, France

🇫🇷

Pneumology department of CHU Lille, Lille, France

and more 16 locations
© Copyright 2025. All Rights Reserved by MedPath